Zhifeng Cheng
Overview
Explore the profile of Zhifeng Cheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
209
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ji L, Ma J, Ma Y, Cheng Z, Gan S, Yuan G, et al.
JAMA Netw Open
. 2025 Mar;
8(3):e2462185.
PMID: 40029660
Importance: Few of the available therapies for type 2 diabetes (T2D) comprehensively address disease burden beyond glycemic control. Examining whether berberine ursodeoxycholate (HTD1801), a first-in-class gut-liver anti-inflammatory metabolic modulator, has...
2.
Lu D, Cheng Z, Zhao T, Yuan L, Gao L, Klabacha J, et al.
Rev Sci Instrum
. 2025 Jan;
96(1.
PMID: 39878577
The use of Highly Oriented Pyrolytic Graphite (HOPG) reflectors is often proposed in the design of X-ray Crystal Spectroscopy (XCS) diagnostic systems for the next-generation tokamak devices, including the ITER...
3.
He Q, Cheng Z, Li Y, Xing X, Li L, Li X, et al.
Diabetes Obes Metab
. 2024 Dec;
27(2):965-975.
PMID: 39632416
Aims: To assess the efficacy and safety of cofrogliptin for impaired glucose tolerance (IGT). Methods: In this multicenter, double-blind, placebo-controlled phase 2 trial, IGT patients were randomized 1:1:1 to receive...
4.
Ji L, Gao L, Cheng Z, Ma G, Li S, Wang H, et al.
Curr Med Res Opin
. 2024 Sep;
40(10):1697-1703.
PMID: 39235266
Objective: To compare the efficacy and safety of insulin degludec biosimilar B01411 (HS-IDeg) with originator insulin degludec-Tresiba (NN-IDeg) in Chinese patients with type 2 diabetes mellitus (T2DM) who were inadequately...
5.
Guo X, Zhang T, Yuan G, Zeng W, Hu Q, Ma J, et al.
JAMA Netw Open
. 2024 Aug;
7(8):e2425614.
PMID: 39158916
Importance: Many patients with diabetic peripheral neuropathic pain (DPNP) experience inadequate relief, despite best available medical treatments. There are no approved and effective therapies for patients with DPNP in China....
6.
Zhang Y, Li J, Feng L, Cheng Y, Shi L, Yang Q, et al.
Am J Cancer Res
. 2024 Aug;
14(7):3294-3316.
PMID: 39113874
Calcium ions (Ca) are crucial in tumorigenesis and progression, with their elevated levels indicating a negative prognosis in Kidney Renal Clear Cell Carcinoma (KIRC). The influence of genes regulating calcium...
7.
Zhao W, Cheng Z, Ji X, Pei Z, Yang K, Huang Z, et al.
Nutr Metab Cardiovasc Dis
. 2024 Jun;
34(9):2217-2225.
PMID: 38866609
Background And Aims: Limited evidence exist regarding the association between ongericimab, a novel recombinant humanized anti-PCSK9 monoclonal antibody, and primary hypercholesterolemia and mixed dyslipidemia. This study aimed to evaluate the...
8.
Zhao L, Cheng Z, Lu Y, Liu M, Chen H, Zhang M, et al.
JAMA
. 2024 May;
332(7):551-560.
PMID: 38819983
Importance: Obesity has become a global public health concern and China has the largest number of affected people worldwide. Objective: To assess the efficacy and safety of treatment with tirzepatide...
9.
Wang X, Qiu M, Cheng Z, Ji X, Chen J, Zhu H, et al.
J Am Heart Assoc
. 2024 May;
13(11):e033669.
PMID: 38818934
Background: A phase 3 trial was conducted to evaluate the efficacy and safety of ongericimab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9, as an add-on treatment to...
10.
Xie L, Han J, Cheng Z, Liu D, Liu J, Xu C, et al.
J Diabetes
. 2024 Apr;
16(4):e13526.
PMID: 38584148
Background: Bexagliflozin and dapagliflozin are sodium-glucose cotransporter-2 (SGLT2) inhibitors. No direct comparison of SGLT2 inhibitors in a randomized controlled trial has been reported to date. Methods: This was a multicenter,...